U.S. Markets close in 43 mins

Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs

HAMILTON, Bermuda, April 08, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it will present preclinical data for KPL-404, a monoclonal antibody inhibitor of the CD40 co-stimulatory receptor, at the Keystone Symposia, Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies, in Breckenridge, CO. 

Details of the presentation are as follows:

  • KPL-404, a CD40 antagonist, blocked antigen-specific antibody responses in an in vivo NHP model and demonstrated strong PK/PD correlation (Poster # 2036) by Sujatha Muralidharan1, Brendan J. Classon1, Karalyne Crowder2, Andrea S.L. Wong2, Yoshinobu Yokota2, Florence Burleson3, Tracy Garron1, Moses Njenga1, John F. Paolini1 will be presented during Poster Session 2 on Tuesday, April 9th, 2019 at 7:30 p.m. Mountain Time in the Breckenridge Ballroom at the Beaver Run Resort. Kiniksa intends to make the materials available through the Investors and Media section of its website (www.kiniksa.com).

About KPL-404
KPL-404 is an investigational humanized monoclonal antibody that is designed to inhibit the CD40-CD40-ligand interaction, a key T-cell co-stimulatory signal critical for B-cell maturation and immunoglobulin class switching. Dysregulation of the CD40-CD40L pathway has been implicated in multiple autoimmune disease pathologies such as Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren’s Syndrome and Grave’s Disease.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa has a pipeline of product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions. For more information, please visit www.kiniksa.com.

1Kiniksa Pharmaceuticals Corp., MA, USA; 2Altasciences Preclinical Seattle LLC, WA, USA; 3Burleson Research Technologies Inc, NC, USA

Every Second Counts!™

Kiniksa Investor and Media Contact
Mark Ragosa
(781) 430-8289
mragosa@kiniksa.com